A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies

作者
Gregory L. Moore,Veronica G. Zeng,Juan E. Diaz,Christine Bonzon,Kendra N. Avery,Rumana Rashid,Jing Qi,Dong Hyun Nam,Jonathan M. Jacinto,Matthew A. Dragovich,Yoon Kyung Kim,Karen P. Balcazar,Charles G. Bakhit,Araz Eivazi,Hanh P. Nguyen,Umesh S. Muchhal,David E. Szymkowski,John R. Desjarlais,Michael Hedvat
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:24 (3): 331-344 被引量:20
标识
DOI:10.1158/1535-7163.mct-24-0327
摘要

T-cell activation is a multistep process requiring T-cell receptor engagement by peptide-MHC complexes (Signal 1) coupled with CD28-mediated costimulation (Signal 2). Tumors typically lack expression of CD28 ligands, so tumor-specific Signal 1 (e.g., neoepitope presentation) without costimulation may be ineffective or even induce T-cell anergy. We designed the bispecific antibody XmAb808 to co-engage the tumor-associated antigen B7-H3 with CD28 to promote T-cell costimulation within the tumor microenvironment. XmAb808 costimulation was measured by its ability to activate and expand T cells and enhance T cell-mediated cancer cell killing in cocultures of human peripheral blood mononuclear cells and cancer cells and in mice engrafted with human peripheral blood mononuclear cells and tumor xenografts. XmAb808 avidly bound cancer cells and stimulated IL2 and IFNγ secretion from T cells cocultured with cancer cells engineered to deliver Signal 1 to T cells via a surface-expressed anti-CD3 antibody. XmAb808 enhanced expression of the antiapoptotic factor Bcl-xL and CD25, promoting survival and IL2-dependent expansion of T cells coupled with increased T cell-mediated cytotoxicity in vitro. XmAb808 combined with an EpCAM×CD3 bispecific antibody to enhance target cell killing through IL2-dependent expansion of CD25+ T cells. This combination also suppressed pancreatic tumor xenograft growth in mice. Furthermore, XmAb808 combined with an anti-programmed cell death protein 1 antibody to suppress breast tumor xenograft growth in mice. XmAb808 as monotherapy and in combination with an anti-programmed cell death protein 1 antibody is currently in clinical development in patients with advanced solid tumors. Our results suggest that XmAb808 may also combine with tumor antigen-targeted anti-CD3 (Signal 1) T-cell engagers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不想打工完成签到,获得积分10
刚刚
刚刚
hehe完成签到,获得积分10
刚刚
Mary完成签到,获得积分10
刚刚
五月的骇客完成签到 ,获得积分10
1秒前
2秒前
彭于晏的应助被受伤白安采纳,获得10
2秒前
2秒前
qingxuan发布了新的文献求助10
3秒前
Mary发布了新的文献求助20
4秒前
遇见完成签到,获得积分10
4秒前
耶耶小豆包完成签到,获得积分10
4秒前
美母猪佩奇完成签到,获得积分10
4秒前
Always完成签到 ,获得积分10
4秒前
11完成签到,获得积分10
5秒前
侯雨润完成签到,获得积分10
6秒前
YYM完成签到 ,获得积分10
6秒前
西西完成签到,获得积分10
6秒前
秣旎完成签到,获得积分10
6秒前
喜悦的绮露完成签到 ,获得积分10
6秒前
lsm完成签到,获得积分10
7秒前
希望天下0贩的0的应助被佩琪采纳,获得10
7秒前
7秒前
丘比特的应助被粒粒采纳,获得10
8秒前
大模型的应助被虚心碧采纳,获得10
8秒前
小欣欣爱学习完成签到,获得积分10
8秒前
Yiding完成签到,获得积分10
8秒前
汤包发布了新的文献求助10
10秒前
CipherSage的应助被平常迎天采纳,获得30
11秒前
11秒前
Tuniverse_发布了新的文献求助10
11秒前
11秒前
WANG发布了新的文献求助10
12秒前
shmily完成签到 ,获得积分10
14秒前
14秒前
15秒前
15秒前
科研通AI65的应助被尘冀等待采纳,获得10
15秒前
11完成签到,获得积分10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640